Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
Diaz LA Jr, Coughlin CM, Weil SC, Fishel J, Gounder MM, Lawrence S, Azad N, O'Shannessy DJ, Grasso L, Wustner J, Ebel W, Carvajal RD. Diaz LA Jr, et al. Among authors: wustner j. Clin Cancer Res. 2015 Mar 15;21(6):1281-8. doi: 10.1158/1078-0432.CCR-14-1829. Epub 2014 Nov 14. Clin Cancer Res. 2015. PMID: 25398449 Free PMC article. Clinical Trial.
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature.
Rybinski K, Imtiyaz HZ, Mittica B, Drozdowski B, Fulmer J, Furuuchi K, Fernando S, Henry M, Chao Q, Kline B, Albone E, Wustner J, Lin J, Nicolaides NC, Grasso L, Zhou Y. Rybinski K, et al. Among authors: wustner j. Oncotarget. 2015 Sep 22;6(28):25429-40. doi: 10.18632/oncotarget.4559. Oncotarget. 2015. PMID: 26327620 Free PMC article.
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer.
O'Shannessy DJ, Bendas K, Schweizer C, Wang W, Albone E, Somers EB, Weil S, Meredith RK, Wustner J, Grasso L, Landers M, Nicolaides NC. O'Shannessy DJ, et al. Among authors: wustner j. Genomics. 2017 Jul;109(3-4):251-257. doi: 10.1016/j.ygeno.2017.04.006. Epub 2017 Apr 25. Genomics. 2017. PMID: 28450240 Free article.
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman JD, Wallin BA. Gupta A, et al. Among authors: wustner j. Cancer Chemother Pharmacol. 2016 Apr;77(4):733-43. doi: 10.1007/s00280-016-2984-z. Epub 2016 Feb 22. Cancer Chemother Pharmacol. 2016. PMID: 26898299 Free PMC article.
A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements.
Sailstad JM, Amaravadi L, Clements-Egan A, Gorovits B, Myler HA, Pillutla RC, Pursuhothama S, Putman M, Rose MK, Sonehara K, Tang L, Wustner JT; Global Bioanalysis Consortium. Sailstad JM, et al. Among authors: wustner jt. AAPS J. 2014 May;16(3):488-98. doi: 10.1208/s12248-014-9582-y. Epub 2014 Mar 29. AAPS J. 2014. PMID: 24682765 Free PMC article. Review.
11 results